Pfiz­er’s RSV vac­cine has 90% ef­fi­ca­cy against se­vere res­pi­ra­to­ry dis­ease

Pfiz­er’s RSV vac­cine was 90% ef­fec­tive at pre­vent­ing the most se­vere out­comes in the first-ever vac­ci­na­tion sea­son, the com­pa­ny said, un­der­scor­ing its po­ten­tial ben­e­fits as …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER